Press Room

News / Aug 09, 2021

Our knowledge is available 365 days for you

Summer series

Knowledge 365 our experts content always available | Hovione

Our knowledge is available 365 days for you.
Count on our multidisciplinary teams to exchange knowledge, ideas, and experience to develop and improve your project. As a specialist integrated CDMO we are dedicated to helping you bring new and off-patent drugs to market faster.

Challenge us

 

Our scientists attend the leading events of the pharma industry throughout the year where they share their knowledge and present their innovative work.
 

Did you miss the articles on Pharmaceutical Technology, Drug Development & Delivery, On-Drug Delivery or Chemistry Today? You are still in time to read them. Access them here: 
 

pharmatech logo | Hovione

 
Drug Development and Delivery Logo | Hovione

 
Moving Beyond
Particle Size Control

Contributors:
João Henriques (Group Leader,
R&D Drug Product Development)
Mafalda Paiva (Group Leader, Analytical Development)


 		 Improving Bioavailability
& Solubility: Each Molecule
Is Unique - Emerging Platforms
Address Extreme Compounds

Contributor: João Henriques
(Group Leader, R&D
Drug Product Development)


 
ondrugdelivery logo | Hovione

 
chemistry today chimica oggi logo | Hovione

 
Semi-Automation in
Inhaler Testing - Exploring
the Potential & Practicalities

Discussion with João Pereira
(Team Leader, R&D Analytical Development)
Raquel Borda d' Água
(Associate Analytical Chemist, R&D Analytical Development; Copley) 


 		 Where Continuous Flow
can help in today’s
Pharmaceutical Industry

Panel Discussion with
Rudi Oliveira
(Scientist, R&D Process
Engineering and Scale-up)

 

 

 

 

 

 

 

Did you miss our presentations at DDF, RDD, DDL or AIChE?
You are still in time to join. Access them here:

 

 

ddf summit 2021 logo | Hovione

 
rdd 2021 logo | Hovione

 

Technology & Innovation

Performance Enhancement Strategies for
Low Solubility APIs – do more with less

Authors: Mafalda Paiva &
João Henriques
 

Workshop Presentation

Fully Integrated
DPI Development
From API To Device

Authors: João Pereira,
Beatriz Noriega Fernandes
aiche 2020 logo | Hovione

 
ddl 2020 logo | Hovione

 

Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals

Reaction Kinetic Model
Application to Speed up Development

Author: Filipe Ataíde
 

Presentation
and Paper

Spray-dried composite
formulation for lung
sustained release

Author: Beatriz Noriega Fernandes

 

Also in the Press Room

See All

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Also in Events

See All